DV
Dividend Vision

VRAX — Virax Biolabs Group Limited Ordinary Shares

Virax Biolabs Group Limited Ordinary Shares (VRAX)

Total return is -99.9% over the past 4.1 years, 205.3 points behind SPY at 105.4%. Its deepest 1-year drawdown was 86.7%.

VRAX is an equity stock fund focused on Virax Biolabs Group Limited ordinary shares, launched in July 2022. The fund provides direct exposure to a single biotech company rather than a diversified portfolio. With no reported dividend distribution rate or expense ratio data currently available, this fund structure may appeal primarily to investors seeking concentrated exposure to Virax Biolabs' potential growth rather than those prioritizing income generation.

VRAX key facts

Asset type
Stock
Asset class
Equity
Inception date
07/21/2022
Last close
$2.86
Market cap
$3,100,283
Average volume
50700.0
Beta
1.331
Payout ratio
0.0
Forward P/E
0.0
EPS
$-12.97